CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
contrast-enhanced magnetic resonance imagingprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00577798
NCT00577798N/ACompleted
CompareCT.gov

Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

University of Nebraska·observational·Posted Dec 20, 2007·Updated Nov 3, 2023

In Brief

An observational study evaluating contrast-enhanced magnetic resonance imaging for Cardiac Toxicity and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy. PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2007
Enrollment StartJan 1, 2008
Primary CompletionMar 1, 2010
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.5 years ago

Interventions

contrast-enhanced magnetic resonance imagingprocedure

Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.